Navigation Links
Novel mechanism found that may boost impaired function of leukemia protein
Date:2/29/2008

NEW YORK, February 29, 2008 A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the development of the blood system and in the production of platelets and immune cells. The findings are published in the March 1, 2008, issue of Genes & Development.

According to the study, investigators identified the methyltransferase enzyme that controls the activity of the normal AML1 protein also called RUNX1 demonstrating its ability to regulate the function of transcription factors, proteins that control cell fate by turning genes on or off. The researchers found that the cellular pathways that regulate the activity of the normal AML1 protein through a process called arginine methylation cannot similarly regulate the activity of AML1-ETO, a protein associated with causing acute leukemia.

Methylation is the process by which methyltransferases catalyze the attachment of a methyl group to DNA or protein in order to regulate gene expression or protein function. Demethylase enzymes that remove methyl groups from proteins have only recently been discovered.

By manipulating the activity of these enzymes, it may be possible to promote the activity of the normal protein, and thereby lessen the impact of the protein that promotes leukemia, said the studys senior author Stephen D. Nimer, MD, Chief of the Hematology Service at MSKCC. We are just beginning to explore whether we can tilt the balance toward a normally functioning AML1 protein in leukemic cells and either trigger their death or their reversion to normal behavior.

There are currently no available drugs that target protein methylation, although two drugs that target DNA methylation are FDA approved for treating patients with myelodysplastic syndromes.

We hope to utilize these new findings to help develop and ultimately test new treatment strategies for patients with either myeloid or lymphoid types of acute leukemia, said the studys first author, Xinyang Zhao, a member of Dr. Nimers laboratory.

Dr. Nimer has been researching the AML1-ETO protein at MSKCC since 1993. He and his colleagues first demonstrated in 1995 that AML1-ETO functions as a transcriptional repressor and dominantly inhibits AML1 function.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3139
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Novel method to reveal drug targets
2. Novel link between excessive nutrient levels and insulin resistance
3. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
4. Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
5. Novel approach strips staph of virulence
6. UCSD research team identifies novel anticancer drug from the sea
7. Novel compound may lessen heart attack damage
8. Novel molecules developed at UB can boost vaccine potency
9. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
10. Novel vaccine concept developed by scientists at the Wistar Institute
11. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Clinical Data Management Solution Providers list for its expertise in eClinical Solutions. DDi ... expertise to serve the technology needs of global clients. DDi provides smarter technology ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, ... demanding job, and no time to decompress, Rabinowitz found herself drawn to a casual ... for its impact on her life, implementing a 20-minute-per-day meditation practice with her team. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016 Laboratory glassware ... in laboratories. These may range from microscope slides to ... is made from borosilicate glass because of its low ... the other hand, started gaining popularity over the past ... to replace glass with plastic in several applications due ...
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
(Date:2/11/2016)... 11, 2016  NOIT™ Research LLC, a private, leading-edge ... Change" campaign to assist needy families in obtaining one ... sold between February 10, 2016 and March 31, 2016, ... family. The NOIT is an auditory stimulus that plays ... language skills. Beth Shier , NOIT ...
Breaking Medicine Technology: